New Therapies for a World Without HIV

HIV treatment has come a long way from the pandemic of the 1980s–1990s to today’s antiretroviral treatments that allow 38 million people to live with HIV successfully. However, over 1 million are newly infected annually, and many lack access to antiviral drugs.

Paul Volberding of University of California San Francisco, who co-created the world’s first comprehensive HIV/AIDS program in 1983 at San Francisco General Hospital and has been a leading voice in HIV treatment guidelines since 1996, will provide a historical perspective on this evolution. Then Moupali Das of Gilead Sciences will discuss Lenacapavir, an injectable drug approved by the FDA in 2022 for multi-drug-resistant HIV, that showed high effectiveness at HIV prevention in 2024 clinical trials.

Register now to explore the past and present of Human Immunodeficiency Virus and discover what barriers to success remain. This ACS Webinar commerates World AIDS Day, is moderated by Cheng Fang of Annovis Bio, and is co-produced with the Science History Institute and ACS Publications.

"What You Will Learn"
-How HIV treatment evolved, from the crisis of the 1980s to today’s long-acting therapies that let millions live full, healthy lives

- Insights from pioneers shaping HIV care, including the creator of the first comprehensive AIDS program and leader behind new prevention breakthroughs like Lenacapavir

- What scientific, social, and global barriers still stand between us and the end of HIV, as well as how they might be overcome